Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of PERT on EPI after Acute Pancreatitis
NCT05480241Unknown
- Sponsor
- ULS Coimbra
- Start
- May 2022
- Primary completion
- Dec 2023
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial in exocrine pancreatic insufficiency (EPI) comparing PERT with Placebo (2 arms). Primary endpoints: Time between acute pancreatitis diagnosis and EPI diagnosis up to 12 months, PERT efficacy assessed by % of successful treatments at 6 months and 2 more. Status: unknown.
02
Drugs
pancrelipase
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT05480241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05480241.